Fig. 1: CAFs treated with cisplatin promote ESCC cell growth and cause chemoresistance in vitro. | Cell Death & Disease

Fig. 1: CAFs treated with cisplatin promote ESCC cell growth and cause chemoresistance in vitro.

From: Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

Fig. 1: CAFs treated with cisplatin promote ESCC cell growth and cause chemoresistance in vitro.

a, b KYSE-30 and KYSE-450 cells displayed increased proliferation and resistance to cisplatin in CM of CAFs pretreated with cisplatin (CM CAFCIS) compared with the control CAFs (CM CAFCTR), cell viability was assessed after treatment with 3 μM cisplatin for 72 h using CCK-8 assay. c, d KYSE-30 and KYSE-450 cells displayed increased proliferation and resistance to cisplatin when co-cultured with CAFCIS compared to CAFCTR; cell viability was assessed after treatment with 3 μM cisplatin for 72 h using CCK-8 assays. The results are representative of three independent experiments. *p < 0.05, **p < 0.01 vs the control group

Back to article page